Literature DB >> 19818305

Apoptosis and cytokines in non-alcoholic steatohepatitis.

Wing-Kin Syn1, Steve S Choi, Anna Mae Diehl.   

Abstract

Non-alcoholic fatty liver disease (NAFLD), one of the commonest causes of chronic liver disease in the United States, represents several overlapping clinicopathological states, ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Although dysregulated lipid accumulation occurs across the spectrum of NAFLD, features of liver cell injury, such as hepatocyte ballooning, cytoskeletal changes (Mallory-Denk bodies), and hepatocyte apoptosis, occur predominantly in NASH and distinguish NASH from simple steatosis. Indeed, NASH is a more serious form of liver damage because cirrhosis and hepatocellular carcinoma are potential outcomes of NASH. Meanwhile, cirrhosis and hepatocellular carcinoma rarely occur in individuals with simple steatosis. Hepatic injury and apoptosis that occur in adults are often dysregulated and accompanied by the accumulation of immune cells, which produce cytokines and growth factors that drive chronic inflammation and may result in fibrosis. This article summarizes the process of apoptosis and roles of putative cytokines in progressive NAFLD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818305      PMCID: PMC2766093          DOI: 10.1016/j.cld.2009.07.003

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  147 in total

1.  Silent cleanup of very early apoptotic cells by macrophages.

Authors:  Kahori Kurosaka; Munehisa Takahashi; Naoko Watanabe; Yoshiro Kobayashi
Journal:  J Immunol       Date:  2003-11-01       Impact factor: 5.422

2.  Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test.

Authors:  Luca Miele; Antonio Grieco; Alessandro Armuzzi; Marcello Candelli; Alessandra Forgione; Antonio Gasbarrini; Giovanni Gasbarrini
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

3.  Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal.

Authors:  Kirsten Lauber; Erwin Bohn; Stefan Martin Kröber; Yi-jin Xiao; Sibylle G Blumenthal; Ralph K Lindemann; Patrizia Marini; Carolin Wiedig; Anke Zobywalski; Shairaz Baksh; Yan Xu; Ingo B Autenrieth; Klaus Schulze-Osthoff; Claus Belka; Gernot Stuhler; Sebastian Wesselborg
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

4.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice.

Authors:  Aimin Xu; Yu Wang; Hussila Keshaw; Lance Yi Xu; Karen S L Lam; Garth J S Cooper
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

5.  Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis.

Authors:  Ali Canbay; Maria Eugenia Guicciardi; Hajime Higuchi; Ariel Feldstein; Steven F Bronk; Robert Rydzewski; Makiko Taniai; Gregory J Gores
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

6.  Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression.

Authors:  Ali Canbay; Ariel E Feldstein; Hajime Higuchi; Nate Werneburg; Annette Grambihler; Steve F Bronk; Gregory J Gores
Journal:  Hepatology       Date:  2003-11       Impact factor: 17.425

7.  Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.

Authors:  Ariel E Feldstein; Ali Canbay; Paul Angulo; Makiko Taniai; Lawrence J Burgart; Keith D Lindor; Gregory J Gores
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

8.  Protection of rat hepatocytes from apoptosis by inhibition of c-Jun N-terminal kinase.

Authors:  Eric L Marderstein; Brian Bucher; Zhong Guo; Xuesheng Feng; Kaye Reid; David A Geller
Journal:  Surgery       Date:  2003-08       Impact factor: 3.982

9.  Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease.

Authors:  F Diraison; Ph Moulin; M Beylot
Journal:  Diabetes Metab       Date:  2003-11       Impact factor: 6.041

10.  Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice.

Authors:  Ariel E Feldstein; Ali Canbay; Maria E Guicciardi; Hajime Higuchi; Steven F Bronk; Gregory J Gores
Journal:  J Hepatol       Date:  2003-12       Impact factor: 25.083

View more
  50 in total

1.  A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis.

Authors:  Vlad Ratziu; Muhammad Y Sheikh; Arun J Sanyal; Joseph K Lim; Hari Conjeevaram; Naga Chalasani; Manal Abdelmalek; Anezi Bakken; Christophe Renou; Melissa Palmer; Robert A Levine; B Raj Bhandari; Melanie Cornpropst; Wei Liang; Benjamin King; Elsa Mondou; Franck S Rousseau; John McHutchison; Mario Chojkier
Journal:  Hepatology       Date:  2011-12-14       Impact factor: 17.425

2.  Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B.

Authors:  Hui Zhang; Qing-Ya Li; Zhi-Zhong Guo; Yan Guan; Jia Du; Yi-Yu Lu; Yi-Yang Hu; Ping Liu; Shuang Huang; Shi-Bing Su
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

Review 3.  Role of cytokines and chemokines in non-alcoholic fatty liver disease.

Authors:  Vincent Braunersreuther; Giorgio Luciano Viviani; François Mach; Fabrizio Montecucco
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 4.  Current and future pharmacologic treatment of nonalcoholic steatohepatitis.

Authors:  Bubu A Banini; Arun J Sanyal
Journal:  Curr Opin Gastroenterol       Date:  2017-05       Impact factor: 3.287

Review 5.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

6.  FOXO1 increases CCL20 to promote NF-κB-dependent lymphocyte chemotaxis.

Authors:  Hongming Miao; Yang Zhang; Zhongyan Lu; Liqing Yu; Lixia Gan
Journal:  Mol Endocrinol       Date:  2012-01-12

7.  Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease.

Authors:  Bryan D Maliken; James E Nelson; Heather M Klintworth; Mary Beauchamp; Matthew M Yeh; Kris V Kowdley
Journal:  Hepatology       Date:  2013-03-14       Impact factor: 17.425

8.  Dendritic cells limit fibroinflammatory injury in nonalcoholic steatohepatitis in mice.

Authors:  Justin R Henning; Christopher S Graffeo; Adeel Rehman; Nina C Fallon; Constantinos P Zambirinis; Atsuo Ochi; Rocky Barilla; Mohsin Jamal; Michael Deutsch; Stephanie Greco; Melvin Ego-Osuala; Usama Bin-Saeed; Raghavendra S Rao; Sana Badar; Juan P Quesada; Devrim Acehan; George Miller
Journal:  Hepatology       Date:  2013-06-24       Impact factor: 17.425

9.  Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis.

Authors:  Naim Alkhouri; Agnieszka Gornicka; Michael P Berk; Samjhana Thapaliya; Laura J Dixon; Sangeeta Kashyap; Philip R Schauer; Ariel E Feldstein
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

10.  Peroxiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model.

Authors:  Atsunori Nabeshima; Sohsuke Yamada; Xin Guo; Akihide Tanimoto; Ke-Yong Wang; Shohei Shimajiri; Satoshi Kimura; Takashi Tasaki; Hirotsugu Noguchi; Shohei Kitada; Teruo Watanabe; Junichi Fujii; Kimitoshi Kohno; Yasuyuki Sasaguri
Journal:  Antioxid Redox Signal       Date:  2013-05-03       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.